Moneycontrol PRO
HomeNewsBusinessMarketsSEBI reaches out to market participants; discusses capital raising, disclosure issues

SEBI reaches out to market participants; discusses capital raising, disclosure issues

FICCI appreciated the proactive efforts being taken by Sebi in the wake of developments related to COVID-19.

May 13, 2020 / 19:19 IST

Regulator Sebi on Wednesday discussed several issues pertaining to raising of capital and corporate debt market with corporates as well as promised to look into the challenges being faced by them due to the COVID-19 crisis. In a conference call with the Federation of Indian Chambers of Commerce and Industry (FICCI), Sebi Chairman Ajay Tyagi apprised the industry leaders of various steps already taken by the market regulator and promised to look into the issues raised by them.

This was part of the series of meetings that the Securities and Exchange Board of India (Sebi) is having with various stakeholders, the regulator said in a statement.

Sebi had earlier interacted with the Confederation of Indian Industry (CII).

FICCI appreciated the proactive efforts being taken by Sebi in the wake of developments related to COVID-19.

Sangita Reddy and Sunil Sanghai were among the representatives of FICCI who attended the conference call, while Tyagi was also joined by other senior officials from Sebi.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Several issues concerning the industry in light of the lockdown due to COVID-19 were discussed in the meeting. This included raising  of capital, corporate debt market and disclosures.

Tyagi said Sebi has been responding to market developments through appropriate measures in consultation with various stakeholders.

He further said Sebi is in regular touch with the government, Reserve Bank of India and other regulators on various issues.

Sebi has taken several proactive measures in easing the corporates' regulatory compliance burden by introducing relaxations like extension of date for filings to be made to stock exchanges like quarterly and annual financial results, corporate governance reports, shareholding pattern, among others, for listed entities.

The regulator has also granted a one-time relaxation in primary market fund raising norms to make it easier for companies to raise capital amid the COVID-19 pandemic.

Rights issues are now considered successful if the minimum subscription received is 75 per cent, as opposed to 90 per cent earlier.

Further, in case of fast track issues, the eligibility criteria of average market capitalisation of public shareholding of the issuer has been relaxed to Rs 100 crore from the earlier Rs 250 crore.

Sebi has also extended the validity of observation letters issued by it for initial public offerings (IPOs) and rights issues as well as new fund offer (NFO) documents for mutual funds by six months.

Besides, Sebi has given relaxations for market intermediaries such as stock brokers, depository participants and share transfer agents (RTAs).

Deadlines for implementation of stewardship code for mutual funds, overhaul of regulations governing portfolio management services (PMS), mutual funds and alternative investment fund have been extended too.

To ensure orderly functioning of the market, Sebi has put in place adequate risk management measures.

Follow our full coverage of the coronavirus pandemic here.

PTI
first published: May 13, 2020 07:15 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347